Ranbaxy Labs Announces Tadalafil Impotence Treatment
Ranbaxy Laboratories Limited announced the launch of its brand, Forzest (Tadalafil) in India. Forzest generic Cialis is the most recently approved prescription medicine for the treatment of Impotence/Erectile Dysfunction (ED) in men.
Currently, the available oral specific medication for management of impotence is Sildenafil Citrate which is valued at Rs 70 Cr in India. In the case of Sildenafil, the pill has to be taken one hour before, since Forzest has an advantage over Sildenafil in terms of longer therapeutic window as it acts faster and more importantly can be taken any time up to 36 hours in advance. Given these advantages, Tadalafil gives “freedom of choice” and has been called as the weekend pill.
Impotence is a seriously under-diagnosed condition, which largely goes untreated due to embarrassment of patients. It is estimated that about 150 million people suffer from impotence and about 9 out of every 10 men do not seek treatment.
In India, it is estimated that about 50 million patients suffer from impotence. Studies also indicate that men with Diabetes have 3-fold higher incidence of ED and 50% of them develop the condition within 10 years of being diagnosed with Diabetes.
Commenting on the product launch, Mr. Sanjeev I. Dani, Regional Director, India operations, Ranbaxy, said, “Introduction of Forzest will provide Indian doctors with best-in-class and contemporary therapeutic option for management of Erectile Dysfunction, which also gives greater time window to the patients”.
Ranbaxy Laboratories Limited, India’s largest Rx pharmaceutical company, manufactures and markets branded generic drugs and Active Pharmaceutical Ingredients. Ranbaxy’s continued focus on R&D has resulted in several approvals in developed markets and significant progress in New Drug Discovery Research.
Ranbaxy’s foray into Novel Drug Delivery Systems has led to proprietary “platform technologies” resulting in a number of products under development. The Company is selling its products in over 100 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 34 countries and manufacturing operations in 7 countries.